EdgeRock Capital’s Gilead Sciences GILD Stock Holding History

EdgeRock Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-102	Closed	-$6K	–	192
2022 Q3	$6K	Buy	+102	New	+$6.43K	﹤0.01%	224

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EdgeRock Capital's GILD Position: Q4 2022 in Review

EdgeRock Capital sold out of Gilead Sciences (GILD) in Q4 2022, closing a stake of 102 shares — an estimated $6K sold.

EdgeRock Capital first reported a position in GILD in Q3 2022 and held it in 1 quarter. The position peaked at $6K in Q3 2022. 1,767 funds tracked by Wall St. Rank hold GILD as of Q4 2022.

EdgeRock Capital reported no remaining Gilead Sciences position as of Q4 2022 after selling out during the quarter.
EdgeRock Capital sold 102 Gilead Sciences shares in Q4 2022, an estimated $6K.
EdgeRock Capital first reported a position in Gilead Sciences in Q3 2022 and held it in 1 quarter.
EdgeRock Capital's Gilead Sciences position peaked at $6K in Q3 2022.
1,767 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.

Based on EdgeRock Capital's 13F filing for Q4 2022, filed 14 Feb 2023.